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Abstract
Purpose—We evaluated Florida-based physicians’ awareness and use of the Centers for Disease 
Control and Prevention’s (CDC) “You are the Key” campaign website, including messages to 
support physicians’ human papillomavirus (HPV) vaccine recommendations.
Methods—Using closed-ended and free-text survey items, physicians’ (n = 355) practices related 
to HPV vaccination recommendations for males and use of the CDC’s materials were assessed. 
Descriptive statistics were calculated for closed-ended questions, and thematic analysis was 
conducted on free-text responses.
Results—Over half of physicians were aware of the CDC’s website (n = 186; 57.9%); of those 
aware, fewer than half reported using the website (n = 86; 46.2%). Slightly more than half reported 
awareness of the CDC’s messages (n = 178; 55.3%); however, less than one-third of those aware 
reported using them (n = 56; 31.5%). Physicians’ comments on the CDC’s messages were 
favorable; 78.6–93.2% said they would use a message in clinic.
Conclusion—Additional research is needed to identify the best mechanisms for resource 
dissemination and to understand why physicians do not use these messages, despite favorable 
attitudes.
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Introduction
Approximately 63% of penile cancers, 91% of anal cancers, and 72% of oropharyangeal 
cancers are linked to vaccine-type human papillomavirus (HPV) infection [1]. The three-
dose series of quadrivalent HPV (HPV4) vaccine tested in clinical trials demonstrated high 
immunogenicity levels, reductions in genital lesions, and reductions in precancerous 
anogenital lesions in males [2, 3]. Recent studies confirmed high immunogenicity levels 
from the three-dose series of 9-valent HPV (9vHPV) vaccine [4, 5]. Consequently, the 
Advisory Committee on Immunization Practices (ACIP) recommends routine HPV 
vaccination for males ages 11–12; beginning at age 9 with catch-up vaccination ages 13–21, 
and up to age 26 for immunocompromised men or men who have sex with men [6]. In 2014, 
HPV vaccine coverage with 3 doses among males ages 13–17 was 22% in the United States 
(US) and 18% in Florida (range: 9% in Alabama to 43% in Rhode Island) [7]. Florida has 
among the nation’s highest rates of HPV-related diseases in males, including the 5th highest 
rate of anal cancer [8]. Given the established efficacy of preventing HPV infections that 
cause anal and penile cancer [2, 3], HPV vaccination has tremendous potential for primary 
prevention in males [9, 10].
HPV vaccination among adolescent males is strongly predicted by physician 
recommendation [11–13]. Organizations including the Centers for Disease Control and 
Prevention (CDC) [14] and the President’s Cancer Panel [15] advocate increasing physician 
recommendation as the primary approach to achieve the Healthy People 2020 goal of 80% 
of 13–15 year old adolescents receiving 3 doses of HPV vaccine [16]. However, physicians’ 
self-reported rates of strongly recommending HPV vaccine for males ages 11–12 in the US 
remains low for pediatricians (52%) and family medicine physicians (41%) [17]. Guidance 
for physicians’ communication with parents about HPV vaccine is critical to increasing 
vaccination [11, 18]. Given the limited time in the medical encounter [19], providing 
physicians with brief messages that address parents’ main concerns about HPV vaccine may 
effectively promote vaccine recommendation in clinic [20].
To support physicians’ recommendations, the CDC launched the “You are the Key” 
campaign in May 2013 [21]. This campaign included the website, “HPV Vaccine Resources 
for Healthcare Professionals” to support healthcare professionals provide HPV vaccination 
recommendations to parents of adolescent patients (http://www.cdc.gov/hpv/hcp/
index.html). One page entitled, “Tips and Time-savers for Talking with Parents about HPV 
Vaccine” (referred to hereafter as “Tips and Time-savers”) includes nine messages 
addressing common parental concerns to use when discussing HPV vaccine with parents. 
However, little is known about physicians’ use of the messages in practice.
We evaluated pediatric and family physicians’ use of the CDC’s “You are the Key” 
campaign by exploring the reach component of RE-AIM, an evaluation model that provides 
framework for appraising impact of a multilevel health intervention in a real-world setting 
[22]. In this model, reach refers to the number and representativeness of the target 
population who receive and adopt the intervention/program. We evaluated reach in this study 
by assessing the number and representativeness of physicians who were aware of and used 
the campaign messages when recommending HPV vaccine for their adolescent male 
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patients. In addition, physicians’ feedback was solicited on the campaign messages to 
inform our understanding of messages’ appeal to physicians.
Methods
Procedure
Participant recruitment and the survey instrument are described in detail elsewhere [23, 24] 
and are summarized below.
Recruitment
A mailing list of Florida-based pediatricians and family medicine physicians from an 
American Medical Association Physician Masterfile licensee was obtained. Study exclusion 
criteria were: 1) trainee status (i.e., residents and fellows), 2) locum tenens, 3) non-patient 
care reported as their primary activity, 4) age 65 years or older, and 5) post office box listed 
as an address. Pediatric and family physicians (n = 770) were randomly selected based on 
their proportional representation in the Florida physician primary care workforce. After 
receiving institutional review board approval, we began a six-wave mailing approach with 
pre-notice postcards mailed in May 2014, and ending with a final reminder to non-
responders in August 2014. We received 367 completed surveys; after accounting for 
undeliverable surveys (n = 36) and ineligible respondents (n = 10), the overall response rate 
was approximately 51% (367 / [770-36-10]).
Measurement
The 49-item survey assessed physicians’ HPV vaccination recommendation practices, 
personal and perceived parental barriers to HPV vaccination, HPV-related knowledge, 
demographic characteristics, practice setting, strategies for remembering to discuss HPV 
vaccine with male patients, and current use of information/support regarding HPV 
vaccination. Specifically, the CDC’s “You are the Key” campaign resources reach was 
assessed using the following questions: (1) Do you use the “HPV Vaccine Resource for 
Healthcare Professionals” website provided by the Centers for Disease Control and 
Prevention to guide your discussion of HPV vaccination with parents of male patients? (2) 
Do you use the “Tips and Time-savers for Talking with Parents about HPV vaccine” tip 
sheet provided by the Centers for Disease Control and Prevention to guide your discussion 
of HPV vaccination with parents of male patients? Response options were: yes, no, or I am 
unaware of this website. Awareness was operationalized by combining the “yes” and “no” 
responses.
The CDC’s “Tips and Time-savers” document includes nine messages for physicians to use 
when addressing parents’ questions about HPV. To reduce potential respondent burden, we 
created and randomly assigned physicians to one of three survey versions (referred to as 
versions A, B, C in this manuscript). Each survey had three of the nine messages; A1-A3, 
B1-B3, and C1-C3. Following each message, physicians were asked: Would you use this 
message when discussing HPV vaccine with parents of male patients in your clinical 
practice? Response options were: yes, no, or unsure. In addition, after each message, 
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physicians were asked to: Please provide any additional feedback that you feel is important 
regarding the recommended message.
Data Analysis
Frequencies for demographic information and closed-ended responses were calculated using 
SPSS (version 21). All free-text responses were provided in direct response to one of the 
“Tips and Time-savers” messages. However, upon initial review of all comments, themes 
were found across messages. Therefore, rather than analyzing specific responses to 
individual messages, the comments were considered holistically to identify particular 
message features. For example, the response “Needs to be simplified in laymen’s terms for 
most patients” was categorized as: messages need to consider audiences’ literacy level. 
Using thematic analysis, one researcher reviewed and categorized all free-text responses. All 
responses were independently coded a second time by a research assistant to assess coding 
scheme reliability and validity. Cohen’s Kappa of .862 was achieved, an acceptable level of 
agreement.
Results
Participants
Of the 770 physicians invited to participate in this study, 367 completed the survey. 
Individuals who reported not providing care to males age 9–26 were excluded from analysis 
for a final analytic sample of 355. Approximately half of physicians were female (51.0%), 
age ≥50 years (46.1%), specialized in family medicine (49.3%), and saw between 20–29 
patients per day (44.5%). The majority was White (67.7%), non-Hispanic (75.1%), practiced 
for ≥16 years (51.9%), and worked in private practice (67.2%). Approximately one-third 
practiced in an urban setting (37.7%; Table 1). We found no statistically significant 
difference between responding physicians and the larger population of Florida physicians for 
age, sex, and clinical specialty (all p > .05) [24].
Closed-Ended Responses
Over half of physicians were aware of the CDC’s “HPV Vaccine Resources for Healthcare 
Professionals” website (n = 186; 57.9%). A slightly higher proportion of pediatricians (n = 
94; 62.3%) than family medicine physicians (n = 92; 54.1%) reported awareness of the 
website. More than half of family medicine physicians (n = 55; 59.8%) and slightly fewer 
than half of pediatricians (n = 45; 47.9%) who were aware of the website reported not 
using.. Similarly, just over half were aware of the “Tips and Time-savers” messages (n = 
178; 55.3%). Slightly more pediatricians reported being aware of the messages (n = 91; 
59.9%) compared with family medicine physicians (n = 87; 51.1%); a slightly lower 
proportion of pediatricians (n = 58; 63.7%) compared with family medicine physicians (n = 
64; 73.6%) who were aware of the messages, reported not using them.
Approximately equal numbers of participants responded across survey conditions: 112 (of 
257 surveys mailed) responded to survey version A; 120 (of 256) responded to version B; 
and 117 (of 257) responded to version C. Across all conditions, participants indicated they 
would use the messages provided by the CDC when talking with adolescent males’ parents. 
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Responses to each of the nine messages ranged from 78.6% - 93.2% as yes they would use 
the message, 2.6% - 11.1% as no they would not use the message, and 3.4% - 11.1% 
indicating they were unsure if they would use the message (Table 3).
Two messages the highest proportion of participants (93.2%) indicated they would use were 
message C3 about ensuring the patient receives all three doses of the vaccine, and message 
B3 about the efficacy of HPV vaccine. The message the highest proportion of respondents 
(11.1%) indicated uncertainty about using was message C1 regarding the high incidence of 
HPV in the US population. The message the highest proportion of participants (11.1%) 
indicated they would not use was message C2 supporting a personal and professional 
organization endorsement for HPV vaccination (see Table 3 for messages).
Free-Text Responses
Twenty-nine respondents to survey version A, 30 respondents to survey version B, and 29 
respondents to survey version C provided at least one free-text response to the messages. 
Using the 137 free-text responses in conjunction with the closed-ended responses, five 
overarching themes emerged. The themes are organized according to: would use, unsure 
about using, or would not use the message in practice.
Would use the message
Participants were positive about the message: The first theme, approval and perceived 
message utility, reinforced participants’ closed-ended response. For example, the message 
was “Excellent” (B1), or “Simple, yet probably the most important message to get across 
about HPV vaccine” (A1). Participants agreed with the content and message value for their 
patients.
Participants wanted more details or emphasis on message content: Although participants 
reported they would use the message in practice, requests for additional information 
emerged in the written comments. Most requested information related to indications: “need 
to specify what kind of cancer it prevents and safety, efficacy, doses” (A1), or clarification 
about protection against other types of sexually transmitted infections (STIs): “add that HPV 
does not protect against other STDs or pregnancy” (B1).
Messages about cancer prevention resonated with participants; some advised cancer 
prevention should be stressed: “I emphasize the cancer prevention aspect of the vaccine” 
(A1). If the message did not include prevention, participants wrote it should be added.
Participants were uncertainty about the message: Despite indicating they would use the 
message, written responses demonstrated uncertainty about the information in the message: 
“Is it true that it is more effective long term when given at a younger age? This is the reason 
I give ‘on time’ rather than wait, if this is true” (B3), and concern about their understanding 
and vaccine acceptance: “I would, but I’m not sure about giving it to my own twin 12 year 
old boys” (C2).
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Unsure about using the message
Participants anticipated parental skepticism: Participants predicted parental pushback, 
especially related to vaccination for males: “The vaccine has been marketed as preventative 
for cervical cancer. Parents tend to be skeptical about the message of cancer prevention in 
males. Especially if the cancer type is anal cancer” (A1). Other comments focused on 
concerns about vaccine efficacy compared with potential side effects: “Parents are already 
asking me about the recent reports of more serious reactions” (A3).
Participants had personal hesitations about the vaccine: Physicians’ concerns ranged 
from apprehension about the number of vaccines: “Too many vaccines!!! Do you plan to 
make one for all STDs?” (C1), to their suspicions about government organizations: “Do not 
trust the CDC” (A3), to their concerns about vaccine safety relative to HPV-related disease 
susceptibility: “Penile and anal cancers are rare, yet there are recent reports of vaccine 
adverse reactions” (A1).
Would not use the message
Participants worried about the literacy level of the messages: Participants unfavorable to 
the messages were sensitive about the health literacy of the patient population they serve, for 
example: “too long and scientific” (C1) or “too advanced – information should be at a 3rd 
grade level for Medicaid families – this is too difficult” (B3).
Participants were skeptical about the message or the vaccine: Alternatively participants 
wrote in strong personal opinions about their distrust of the vaccine: “too many shots and 
more toxins in these shots???” (C3), and organizations promoting vaccination: “I do not 
agree with organizations that profit from vaccines and pharmaceuticals” (C2). Participants 
also reported disagreement with the messages and the research cited in the messages: “I 
don’t agree with statements” (C1), and “I don’t agree with that research, clinical observation 
says otherwise” (B2). In addition, participants commented on the message about having their 
own children vaccinated, stating: “I do not use myself or family as an example why they 
should or should not be vaccinated” (C2).
Discussion
Physicians are the preferred information source about HPV vaccine [25–27]. Professional 
organizations recommended consistent and strong provider recommendation for HPV 
vaccine [28, 29] as a primary approach to improving HPV vaccination. However, reported 
elsewhere [23], only 30.6% of physicians in this study strongly and consistently 
recommended HPV vaccination for males ages 11–12. Yet few studies explored messages 
promoting HPV vaccination for physicians to use with parents. Thus, we examined reach of 
CDC materials to pediatric and family medicine physicians in Florida.
When presented with the CDC’s messages, 78.6–93.2% of participants indicated they would 
use one of the messages. However, close to half of physicians were unaware of (44.7%) and 
approximately one third did not use (37.9%) the messages. Similarly, close to half were 
unaware of (42.0%) or did not use (31.1%) the CDC’s website. Family medicine physicians’ 
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were less likely to report awareness and use of CDC focused materials than pediatricians. It 
is possible the greater emphasis on prevention in training and practice in pediatrics, 
compared with family medicine [30], resulted in increased awareness and utilization of CDC 
resources among pediatricians. Thus, to reach family medicine physicians, attention should 
be given information source preference.
A study of physicians’ preference for information sources about HPV vaccination found the 
majority of family medicine physicians (~40%) preferred professional organizations [31]. 
Although the CDC campaign was referenced in an article and “Dear Colleague letter” from 
the American Academy of Family Physicians [32], it may have been more effective to 
append the messages to the letter. Alternatively, the CDC mandates the vaccine information 
sheet (VIS) be provided to all parents of children who receive vaccines, pairing the messages 
with the VIS may increase reach.
There are several possible explanations for the contradictory finding that physicians were 
favorable toward the messages, but did not use them in practice. Physicians might have 
previously encountered the CDC website and messages, but did not remember the messages 
until they read them later in the survey. Alternatively, physicians may have developed and 
use messages similar to CDC messages, forget about CDC messages in practice, or do not 
regularly provide HPV vaccine recommendation for adolescent males. The low rates of 
strong and consistent recommendations [23], and findings that physicians’ hold positive 
attitudes toward male HPV vaccination, but do not provide strong recommendations for their 
adolescent male patients [20], suggests the answer may be the latter.
In the current study, physicians aware of, but who would not use the CDC messages 
described concerns about vaccine safety and efficacy and some stated personal skepticism 
about studies referenced in the messages, possibly indicating limited education about HPV 
vaccine for males. Consistently, a review of studies found gaps in provider knowledge about 
HPV vaccine indications in males negatively affected HPV recommendation [33]. 
Additional educational opportunities for physicians in these areas may increase the 
consistency and strength of HPV vaccine recommendation for male adolescents.
Responses reflected physicians’ consideration of their patient population. First, physicians 
were concerned about parental resistance. Previous findings indicate physicians are 
favorable toward, yet are reluctant to recommend HPV vaccine to adolescent males due to 
potential negative parental reactions [34–36]. However, research suggests physicians’ 
estimates of parental attitudes toward HPV vaccine importance are lower than parent reports 
[37, 38]. In addition, physicians were concerned about the literacy levels of the message. 
Thus, developing training modules addressing providers’ misperceptions about parental 
attitudes, self-efficacy to overcome parental resistance [36], and skills to develop or modify 
messages to accommodate low health literacy may increase the frequency of HPV vaccine 
recommendation. Finally, participants wanted messages to clarify STI protection from HPV 
vaccine. An earlier study identified cases in which both adolescents and their parents 
believed HPV vaccine was protective against herpes, gonorrhea, and HIV [39]. Thus, such 
requests may stem from participants’ clinical experience, and should be considered in future 
messages.
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Overall, information requests in this study parallels results from previous studies [23, 39], 
and are consistent with findings that adolescents’ parents require substantial amounts of 
information prior to consenting to HPV vaccination [11]. Research is needed to understand 
why physicians are not using these messages, despite favorable attitudes. Specifically, the 
use of semi-structured interviews and clinic observation may uncover barriers to message 
use in clinical settings and identify potential intervention strategies to address such barriers. 
Furthermore, additional testing should be conducted with patients to assess whether or not 
the messages promote HPV vaccination among adolescent males, ultimately improving HPV 
vaccine coverage [33].
Limitations
This study is limited to the opinions and perspectives of physicians who completed this 
study; those more interested in, favorable attitudes toward, or opposed to HPV vaccine may 
have been more likely to complete the survey. The low rate of response to the open-ended 
comment section is a limitation. Furthermore, the open-ended section did not provide a 
deeper understanding of respondents’ beliefs that might have been achieved through a semi-
structured interview and follow-up questions. Additional qualitative studies can draw upon 
the results reported here as preliminary evidence for beliefs physicians might hold regarding 
HPV vaccination messages for use with adolescent males and their parents.
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Table 1
Sample characteristics (n = 355)
n (%)*
Physician Characteristics
Gender Female 178 (51.0)
Male 171 (49.0)
Age, groups 30–39 64 (18.3)
40–49 124 (35.5)
50 and older 161 (46.1)
Race White/Caucasian 233 (67.7)
Asian 38 (11.1)
Black/African American 22 (6.4)
Other 51 (14.8)
Ethnicity Non-Hispanic 259 (75.1)
Hispanic 86 (24.9)
Practice Characteristics
Clinical Specialty Family Medicine 174 (49.3)
Pediatrics 155 (44.4)
Other 20 (5.7)
Patients Seen per Day Less than 15 41 (11.8)
15–19 96 (27.6)
20–29 155 (44.5)
30 or more 56 (16.1)
Years Practicing 10 or fewer 100 (29.3)
11–15 64 (18.8)
16 or more 177 (51.9)
Type of Practice Private Practice office 229 (67.2)
Other 112 (32.8)
Geographic Location Urban 129 (37.7)
Suburban 180 (52.6)
Rural/Other 33 (9.7)
*
Responses may not sum to 100% due to missing data.
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